- Home
- SNCY vs TECX Comparison
SNCY vs TECX Comparison
Compare SNCY & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCY
- TECX
- Stock Information
- Founded
- SNCY 1982
- TECX 2019
- Country
- SNCY United States
- TECX United States
- Employees
- SNCY N/A
- TECX N/A
- Industry
- SNCY Air Freight/Delivery Services
- TECX
- Sector
- SNCY Consumer Discretionary
- TECX
- Exchange
- SNCY Nasdaq
- TECX Nasdaq
- Market Cap
- SNCY 805.7M
- TECX 647.7M
- IPO Year
- SNCY 2021
- TECX 2018
- Fundamental
- Price
- SNCY $16.18
- TECX $40.90
- Analyst Decision
- SNCY Buy
- TECX Strong Buy
- Analyst Count
- SNCY 6
- TECX 5
- Target Price
- SNCY $18.67
- TECX $72.25
- AVG Volume (30 Days)
- SNCY 737.0K
- TECX 118.2K
- Earning Date
- SNCY 02-03-2025
- TECX 02-24-2025
- Dividend Yield
- SNCY N/A
- TECX N/A
- EPS Growth
- SNCY N/A
- TECX N/A
- EPS
- SNCY 0.82
- TECX N/A
- Revenue
- SNCY $1,060,877,000.00
- TECX N/A
- Revenue This Year
- SNCY $4.23
- TECX N/A
- Revenue Next Year
- SNCY $7.04
- TECX N/A
- P/E Ratio
- SNCY $19.81
- TECX N/A
- Revenue Growth
- SNCY 2.87
- TECX N/A
- 52 Week Low
- SNCY $9.22
- TECX $1.40
- 52 Week High
- SNCY $16.46
- TECX $53.41
- Technical
- Relative Strength Index (RSI)
- SNCY 62.23
- TECX 42.12
- Support Level
- SNCY $15.40
- TECX $37.07
- Resistance Level
- SNCY $16.46
- TECX $50.09
- Average True Range (ATR)
- SNCY 0.63
- TECX 3.22
- MACD
- SNCY 0.08
- TECX -0.72
- Stochastic Oscillator
- SNCY 88.69
- TECX 26.07
About SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.